BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

229 related articles for article (PubMed ID: 22407457)

  • 1. Development of a rapid and practical mutation screening assay for human lung adenocarcinoma.
    Choi H; Kratz J; Pham P; Lee S; Ray R; Kwon YW; Mao JH; Kang HC; Jablons D; Kim IJ
    Int J Oncol; 2012 Jun; 40(6):1900-6. PubMed ID: 22407457
    [TBL] [Abstract][Full Text] [Related]  

  • 2. EGFR/KRAS/BRAF mutations in primary lung adenocarcinomas and corresponding locoregional lymph node metastases.
    Schmid K; Oehl N; Wrba F; Pirker R; Pirker C; Filipits M
    Clin Cancer Res; 2009 Jul; 15(14):4554-60. PubMed ID: 19584155
    [TBL] [Abstract][Full Text] [Related]  

  • 3. EGFR, ERBB2, and KRAS mutations in Korean non-small cell lung cancer patients.
    Bae NC; Chae MH; Lee MH; Kim KM; Lee EB; Kim CH; Park TI; Han SB; Jheon S; Jung TH; Park JY
    Cancer Genet Cytogenet; 2007 Mar; 173(2):107-13. PubMed ID: 17321325
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Molecular changes of epidermal growth factor receptor (EGFR) and KRAS and their impact on the clinical outcomes in surgically resected adenocarcinoma of the lung.
    Kim YT; Kim TY; Lee DS; Park SJ; Park JY; Seo SJ; Choi HS; Kang HJ; Hahn S; Kang CH; Sung SW; Kim JH
    Lung Cancer; 2008 Jan; 59(1):111-8. PubMed ID: 17904685
    [TBL] [Abstract][Full Text] [Related]  

  • 5. A subset of lung adenocarcinomas and atypical adenomatous hyperplasia-associated foci are genotypically related: an EGFR, HER2, and K-ras mutational analysis.
    Sartori G; Cavazza A; Bertolini F; Longo L; Marchioni A; Costantini M; Barbieri F; Migaldi M; Rossi G
    Am J Clin Pathol; 2008 Feb; 129(2):202-10. PubMed ID: 18208799
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Unique Genetic and Survival Characteristics of Invasive Mucinous Adenocarcinoma of the Lung.
    Shim HS; Kenudson M; Zheng Z; Liebers M; Cha YJ; Hoang Ho Q; Onozato M; Phi Le L; Heist RS; Iafrate AJ
    J Thorac Oncol; 2015 Aug; 10(8):1156-62. PubMed ID: 26200269
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Tumor gene mutations and messenger RNA expression: correlation with clinical response to icotinib hydrochloride in non-small cell lung cancer.
    Ren GJ; Zhao YY; Zhu YJ; Xiao Y; Xu JS; Shan B; Zhang L
    Chin Med J (Engl); 2011 Jan; 124(1):19-25. PubMed ID: 21362302
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Mutations of the epidermal growth factor receptor gene in lung cancer: biological and clinical implications.
    Kosaka T; Yatabe Y; Endoh H; Kuwano H; Takahashi T; Mitsudomi T
    Cancer Res; 2004 Dec; 64(24):8919-23. PubMed ID: 15604253
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Pleuro-pulmonary solitary fibrous tumors: a clinicopathologic, immunohistochemical, and molecular study of 88 cases confirming the prognostic value of de Perrot staging system and p53 expression, and evaluating the role of c-kit, BRAF, PDGFRs (alpha/beta), c-met, and EGFR.
    Schirosi L; Lantuejoul S; Cavazza A; Murer B; Yves Brichon P; Migaldi M; Sartori G; Sgambato A; Rossi G
    Am J Surg Pathol; 2008 Nov; 32(11):1627-42. PubMed ID: 18753943
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Detection by denaturant gradient gel electrophoresis of tumor-specific mutations in biopsies and relative bronchoalveolar lavage fluid from resectable non-small cell lung cancer.
    Ferretti G; Curigliano G; Pastorino U; Cittadini A; Flamini G; Calabrò MG; De Pas T; Orlando L; Mandalà M; Colleoni M; Spaggiari L; Granone PL; Pagliari G; de Braud F; Fazio N; Goldhirsch A
    Clin Cancer Res; 2000 Jun; 6(6):2393-400. PubMed ID: 10873091
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Micropapillary lung adenocarcinoma: EGFR, K-ras, and BRAF mutational profile.
    De Oliveira Duarte Achcar R; Nikiforova MN; Yousem SA
    Am J Clin Pathol; 2009 May; 131(5):694-700. PubMed ID: 19369630
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Clinical significance of BRAF gene mutations in patients with non-small cell lung cancer.
    Kobayashi M; Sonobe M; Takahashi T; Yoshizawa A; Ishikawa M; Kikuchi R; Okubo K; Huang CL; Date H
    Anticancer Res; 2011 Dec; 31(12):4619-23. PubMed ID: 22199339
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Patterns of EGFR, HER2, TP53, and KRAS mutations of p14arf expression in non-small cell lung cancers in relation to smoking history.
    Mounawar M; Mukeria A; Le Calvez F; Hung RJ; Renard H; Cortot A; Bollart C; Zaridze D; Brennan P; Boffetta P; Brambilla E; Hainaut P
    Cancer Res; 2007 Jun; 67(12):5667-72. PubMed ID: 17575133
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Detection of epidermal growth factor receptor and human epidermal growth factor receptor 2 activating mutations in lung adenocarcinoma by high-resolution melting amplicon analysis: correlation with gene copy number, protein expression, and hormone receptor expression.
    Willmore-Payne C; Holden JA; Layfield LJ
    Hum Pathol; 2006 Jun; 37(6):755-63. PubMed ID: 16733218
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Rapid and simple detection of hot spot point mutations of epidermal growth factor receptor, BRAF, and NRAS in cancers using the loop-hybrid mobility shift assay.
    Matsukuma S; Yoshihara M; Kasai F; Kato A; Yoshida A; Akaike M; Kobayashi O; Nakayama H; Sakuma Y; Yoshida T; Kameda Y; Tsuchiya E; Miyagi Y
    J Mol Diagn; 2006 Sep; 8(4):504-12. PubMed ID: 16931592
    [TBL] [Abstract][Full Text] [Related]  

  • 16. k-ras mutation and occupational asbestos exposure in lung adenocarcinoma: asbestos-related cancer without asbestosis.
    Nelson HH; Christiani DC; Wiencke JK; Mark EJ; Wain JC; Kelsey KT
    Cancer Res; 1999 Sep; 59(18):4570-3. PubMed ID: 10493509
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Reappraisal of K-ras and p53 gene mutations in the recurrence of Dukes' B2 rectal cancer after curative resection.
    Liang JT; Cheng YM; Chang KJ; Chien CT; Hsu HC
    Hepatogastroenterology; 1999; 46(26):830-7. PubMed ID: 10370622
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Mutational screening of RET, HRAS, KRAS, NRAS, BRAF, AKT1, and CTNNB1 in medullary thyroid carcinoma.
    Schulten HJ; Al-Maghrabi J; Al-Ghamdi K; Salama S; Al-Muhayawi S; Chaudhary A; Hamour O; Abuzenadah A; Gari M; Al-Qahtani M
    Anticancer Res; 2011 Dec; 31(12):4179-83. PubMed ID: 22199277
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Somatic mutations of the HER2 kinase domain in lung adenocarcinomas.
    Shigematsu H; Takahashi T; Nomura M; Majmudar K; Suzuki M; Lee H; Wistuba II; Fong KM; Toyooka S; Shimizu N; Fujisawa T; Minna JD; Gazdar AF
    Cancer Res; 2005 Mar; 65(5):1642-6. PubMed ID: 15753357
    [TBL] [Abstract][Full Text] [Related]  

  • 20. EGFR mutations in non-small-cell lung cancer: analysis of a large series of cases and development of a rapid and sensitive method for diagnostic screening with potential implications on pharmacologic treatment.
    Marchetti A; Martella C; Felicioni L; Barassi F; Salvatore S; Chella A; Camplese PP; Iarussi T; Mucilli F; Mezzetti A; Cuccurullo F; Sacco R; Buttitta F
    J Clin Oncol; 2005 Feb; 23(4):857-65. PubMed ID: 15681531
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.